Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: A meta-analysis of randomized clinical trials

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 347-356

  Castells, Xavier ^a   Cunill, Ruth ^b   Capellà, Dolors ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

Adulthood; All cause treatment discontinuation; Attention deficit hyperactivity disorder; Meta analysis; Methylphenidate

Indexed keywords

DEXMETHYLPHENIDATE; METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; ODDS RATIO; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84877103364     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1390-7     Document Type: Article

References (56)

1. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, Girolamo D (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402-409
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627
3. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204-211
4. Biederman J (2004) Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 65[Suppl 3]:3-7
5. Langley K, Fowler T, Ford T, Thapar AK, van den Bree M, Harold G, Owen MJ, O'Donovan MC, Thapar A (2010) Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry 196:235-240
6. Levin FR, Evans SM, McDowell DM, Kleber (1998) Methylphenidate treatment for cocaine abusers with attention-deficit hyperactivity disorder: a pilot study. J Clin Psychiatry 59:300-305
7. Barkley RA, Murphy KR, Dupaul GI, Bush T (2002) Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 8:655-672
8. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67:524-540
9. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25:157-169
10. Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71:754-763
11. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733-744
12. Godfrey J (2009) Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 23:194-205
13. Merkel RL Jr, Kuchibhatla A (2009) Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I. Expert Opin Drug Saf 8:655-668
14. Rösler M, Casas M, Konofal E, Buitelaar J (2010) Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 11:684-698
15. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines, 3rd edn. CADDRA, Toronto
16. Dodson WW (2005) Pharmacotherapy of adult ADHD. J Clin Psychol 61:589-606
17. National Institute for Health and Clinical Excellence (NICE) (2008) Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Clinical guidelines CG72, September 2008. NICE, London
18. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S, British Association for Psychopharmacology (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10-41
19. Swanson J (2003) Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs 17:117-131
20. Hollingworth SA, Nissen LM, Stathis SS, Siskind DJ, Varghese JM, Scott JG (2011) Australian national trends in stimulant dispensing: 2002-2009. Aust N Z J Psychiatry 45:332-336
21. Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A (2012) Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf. 21(4):435-41
22. Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LT (2003) Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 67:466-468
23. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992-1001
24. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E, European Guidelines Group (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20:17-37
25. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A (2007) Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 120:1494-1501
26. Ramos-Quiroga JA, Casas M (2011) Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs 25:17-36
27. Weiss MD, Gadow K, Wasdell MB (2006) Effectiveness outcomes in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67[Suppl 8]:38-45
28. Egger M, Dickersin K, Davey Smith D (2007) Problems and limitations in conducting systematic reviews. In: Egger M, Davey Smith D, Altman DG (eds) Systematic reviews in healthcare. Meta-analysis in context. BMJ Publishing Group, London, pp 43-68
29. Anderson IM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J 310:1433-1438
30. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531-1541
31. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:1306-1315
32. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290-1297
33. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
34. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476-495
35. European Medicine Agency (EMA): Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2010/08/WC500095686.pdf. Accessed 2 Nov 2011
36. Peterson K, McDonagh MS, Fu R (2008) Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berlin) 197:1-11
37. Higgins JPT, Green S (2011) Strategies for addressing heterogeneity. Cochrane Handbook for Systematic Reviews of interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org
38. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31:140-149
39. The Nordic Cochrane Centre (2011) Review Manager (RevMan), ver. 5.1 (computer program). The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen
40. StataCorp LP (2007) STATA ver. 10 (computer program). STataCorp LP, College Station, TX
41. Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T (2009) Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose escalation study. J Clin Psychopharmacol 29:239-247
42. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T (2006) A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829-835, Erratum in: Biol Psychiatry 2007; 61:1402
43. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T (2010) A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 30:549-553
44. Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B (2011) Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry. doi: 10.3109/15622975.2011.600333
45. Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 9:83-90
46. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK (2008) A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatr 63:981-989
47. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93-101
48. Retz W, Rösler M, Ose C, Scherag A, Alm B, Philipsen A, Fischer R, Ammer R (2012) Multiscale assessment of treatment efficacy in adults with ADHD: A randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry 13:48-59
49. Rösler M, Fischer R, Ammer R, Ose C, Retz W (2009) A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120-129
50. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434-443
51. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 57:456-463
52. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group (2007) Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 61:1380-1387
53. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, Pihlgren E (2002) Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286-294
54. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM (2010) Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71:1680-1688
55. Patrick KS, González MA, Straughn AB, Markowitz JS (2005) New methylphenidate formulations for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Drug Deliv 2:121-143
56. Wilens TE, Biederman J, Lerner M, Concerta Study Group (2004) Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 24:36-41